# A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

> **NCT06436183** · PHASE2 · COMPLETED · sponsor: **Apollo Therapeutics Ltd** · enrollment: 62 (actual)

## Conditions studied

- Atopic Dermatitis
- Atopic
- Dermatitis
- Dermatologic Disease
- Eczema
- Eczema Atopic Dermatitis
- Eczema, Atopic

## Interventions

- **DRUG:** Camoteskimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06436183
- **Lead sponsor:** Apollo Therapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-01
- **Primary completion:** 2025-03-26
- **Final completion:** 2025-08-12
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06436183

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06436183, "A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06436183. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*